Metachronous hepatic metastases from gastric carcinoma: A multicentric survey

Abstract Background The treatment of hepatic metastases from gastric cancer is controversial, due to biologic aggressiveness of the disease. Objective To survey the clinical approach to the subset of patients presenting with metachronous hepatic metastases as sole site of recurrence after curative r...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2009-05, Vol.35 (5), p.486-491
Main Authors: Tiberio, G.A.M, Coniglio, A, Marchet, A, Marrelli, D, Giacopuzzi, S, Baiocchi, L, Roviello, F, de Manzoni, G, Nitti, D, Giulini, S.M
Format: Article
Language:English
Subjects:
Aged
Combined Modality Therapy
Female
Gastrectomy - methods
Gastric cancer
Hematology, Oncology and Palliative Medicine
Hepatic metastases
Humans
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Lymphatic Metastasis
Male
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Neoplasm Staging
Neoplasms, Second Primary - pathology
Neoplasms, Second Primary - therapy
Patient Selection
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk Factors
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Surgery
Survival Rate
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The treatment of hepatic metastases from gastric cancer is controversial, due to biologic aggressiveness of the disease. Objective To survey the clinical approach to the subset of patients presenting with metachronous hepatic metastases as sole site of recurrence after curative resection of gastric cancer, focusing on the results achieved by different therapies and to investigate the prognostic factors of major clinical relevance. Methods Retrospective multi-center chart review evaluating 73 patients, previously submitted to D ≥ 2 gastrectomy for gastric cancer, who developed exclusive hepatic recurrence. Prognostic factors related to the patient, to the gastric malignancy and its treatment, and to the metastatic disease and its therapy were evaluated. Results Forty-five patients received supportive care, 17 were submitted to chemotherapy, and 11 to hepatic resection. Survival was independently influenced by the variables T ( p = 0.019), N ( p = 0.05) and G ( p = 0.018) of the gastric primary and by the therapeutic approach to the metastases ( p < 0.005). In particular, T4 gastric cancer, presence of lymph-node metastases and G3 tumor displayed a negative prognostic value. Therapeutic approach to the metastases was the principal prognostic variable: 1, 2, and 3 years survival rates were 22.2%, 4.4% and 2.2%, respectively, for patients without specific treatment; 44.9%, 12.8% and 6.4% after chemotherapy ( p = 0.08) and 80.8%, 30.3% and 20.2% after surgical resection ( p < 0.001). Conclusions Our data suggest some clinical criteria that may facilitate selection of therapy for patients with hepatic recurrence after primary gastric cancer resection. The best survival rates are associated with surgical treatment, which should be chosen whenever possible.
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2008.12.017